Bifogade filer
Oncopeptides AB Year-end Report 2022
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Oncopeptides AB (publ), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, has today published the year-end report 2022.
Financial overview October-December
- Net sales amounted to SEK 0.6 M (-21.7)
- Operating profit amounted to SEK -100.5 M (-389.8)
- Net profit amounted to SEK -91.1 M (-394.0)
- Profit per share, before and after dilution, amounted to SEK -1.01 (-5.23)
- Cash balances at the end of the period amounted to SEK 344.5 M (362.2)
Financial overview January-December
- Net sales amounted to SEK 8.4 M (118.3)
- Operating profit amounted to SEK -349.3 M (-1,420.9)
- Net profit amounted to SEK -338.0 M (-1,430.3)
- Profit per share, before and after dilution, amounted to SEK -4.11 (-19.00)
- Cash balances at the end of the period amounted to SEK 344.5 M (362.2)
Significant events October-December
- New clinical and preclinical data presented at the Annual American Society of Hematology Meeting (ASH).
- Oncopeptides provides update on Pepaxto® US marketing authorization.
- Submission of a Type II variation application for Pepaxti® to the European Medicines Agency (EMA).
- Renewal of loan agreement with the European Investment Bank of the amount 30 MEUR.
- Pepaxti is granted marketing authorization in the UK.
- Phase 3 LIGHTHOUSE data further confirms the clinical benefit of melflufen.
- Commercialization of Pepaxti in Europe initiated in Germany.
Significant events after the reporting period
- Monica Shaw is appointed CEO and takes office on the 4th of January, and Jakob Lindberg assumes role as Chief Scientific Officer.
- Holger Lembrér is appointed CFO and takes office on the 18th of January 2023.
Selected Key Indicators
| (SEK thousand) | 2022 Oct-Dec | 2021 Oct-Dec | 2022 Jan-Dec | 2021 Jan-Dec |
| Net sales | 560 | -21 710 | 8 355 | 118 295 |
| Operating profit | -100 547 | -389 836 | -349 350 | -1 420 917 |
| Profit after tax | -91 098 | -393 991 | -337 951 | -1 430 317 |
| Earnings per share before and after dilution (SEK) | -1.01 | -5.23 | -4.11 | -19.00 |
| Cash flow from operating activities | -77 630 | -446 455 | -420 509 | -1 516 391 |
| Cash at the end of the period | 344 515 | 362 187 | 344 515 | 362 187 |
| R&D costs/operating expenses, % | 57% | 53% | 61% | 46% |
This publication is a translation of the original Swedish text. In the event of inconsistency or discrepancy between the Swedish version and this publication, the Swedish language version shall prevail.
Webcast for investors, analysts and media
Investors, financial analysts, and media are invited to participate in a webcast and a following QnA session at 09:00 CET on the same day. The presentation will be hosted by Monica Shaw, CEO, together with Holger Lembrér, CFO, and Jakob Lindberg, CSO. The presentation will be held in English.
If you wish to participate via the webcast, please use the link below. Via the webcast you can ask written questions.
https://ir.financialhearings.com/oncopeptides-q4-2022
If you wish to participate via teleconference, please register on the link below. After the registration you will be provided a phone number and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.financialhearings.com/teleconference/?id=5004216